Oncternal Therapeutics to Provide Business Update and Report Third Quarter 2022 Financial Results

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) — Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that it will report third quarter 2022 financial results after the U.S. financial markets close on Thursday, November 3, 2022. Oncternal’s management will host a webcast at 2:00 p.m. PT (5:00 p.m. ET) to provide a comprehensive business update and discuss the Company’s financial results.

The live webcast of the call will be available online at investor.oncternal.com and the call will be archived there for at least 30 days.

About Oncternal Therapeutics
Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need. Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer. The lead clinical program is zilovertamab, an investigational monoclonal antibody designed to inhibit the function of Receptor Tyrosine Kinase-Like Orphan Receptor 1 (ROR1). ZILO-301, a global Phase 3 Study to evaluate zilovertamab in combination with ibrutinib for the treatment of patients with relapsed/refractory mantle cell lymphoma (MCL) has been initiated (NCT05431179). Zilovertamab continues to be evaluated in an ongoing Phase 1/2 study in combination with ibrutinib for the treatment of patients with MCL and chronic lymphocytic leukemia (CLL), and this trial was recently amended to include patients with marginal zone lymphoma (MZL). Zilovertamab is also being evaluated in two investigator-initiated studies, including a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL, and in a Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). Oncternal is also moving into the clinic with ONCT-808, an autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1, with an active U.S. IND as of the end of September 2022 for the treatment of patients with relapsed or refractory aggressive B cell lymphoma, including patients who have failed previous CD19 CAR T treatment. The preclinical pipeline also includes ONCT-534, a dual-action androgen receptor inhibitor (DAARI) that is undergoing final IND-enabling studies, as a potential treatment for castration resistant prostate cancer, including those with unmet medical need due to resistance to approved, standard of care androgen receptor inhibitors. More information is available at https://oncternal.com/.

Contact Information:

Investors
Richard Vincent
858-434-1113
rvincent@oncternal.com

Media
Corey Davis, Ph.D.
LifeSci Advisors
212-915-2577
cdavis@lifesciadvisors.com

Staff

Recent Posts

Flower Expo Returns to Michigan and Illinois This Summer Following Blockbuster Northeast Event

Two-day cannabis trade events will connect brands, dispensaries, and budtenders for networking, product showcases, and…

15 hours ago

Sage Healthspan Launches AI-Powered, Privacy-First Wellness App to Bridge Critical Gaps in Preventative Healthcare

Orange County, California, June 27, 2025 (GLOBE NEWSWIRE) -- Sage Healthspan, a California-based digital health…

15 hours ago

theranos Calls on President Trump to Pardon Elizabeth Holmes

You Cannot Silence the SciencePALM BEACH, Fla., June 27, 2025 (GLOBE NEWSWIRE) -- In less…

15 hours ago

Freeze Drying Equipment Market to Surge from USD 4.9 Billion to USD 8.4 Billion by 2032 – Meticulous Research®

Lyophilization Process Innovation, Food Preservation Demand, and Pharmaceutical Industry Expansion Drive 7.9% CAGR Growth Across…

24 hours ago